COMMUNIQUÉS West-GlobeNewswire

BridgeBio Pharma Announces Pricing of Its Initial Public Offering
27/06/2019
PALO ALTO, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) today announced the pricing of its initial public offering of 20,500,000 shares of its common stock at a price to the public of $ [...]
Abeona Therapeutics nomme le Dr. Victor Paulus au poste de premier vice-président des affaires réglementaires
27/06/2019
NEW YORK et CLEVELAND, 27 juin 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq : ABEO), leader entièrement intégré de la thérapie génique et cellulaire, a annoncé aujourd'hui la nomination du Dr. Victor Paulus [...]
Adaptive Biotechnologies Announces Pricing of Initial Public Offering
27/06/2019
SEATTLE, June 26, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune [...]
Hatch Medical Signs Manufacturing and Distribution Pact with Argon Medical Devices
26/06/2019
ATLANTA, June 26, 2019 (GLOBE NEWSWIRE) -- Medical device incubator and technology brokerage firm, Hatch Medical, L.L.C., recently announced the completion of a licensing agreement with Argon Medical Devices, Inc., a [...]
Ascent Industries Provides Update From Special General Meeting
26/06/2019
VANCOUVER, British Columbia, June 26, 2019 (GLOBE NEWSWIRE) -- Ascent Industries Corp. ( CSE: ASNT ) (“ Ascent ” or the “ Company ”) today announced that all resolutions were passed by the requisite majority at its [...]
ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC
26/06/2019
LYON, France and CAMBRIDGE, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug [...]
ERYTECH annonce le recrutement de la première patiente dans son étude clinique de phase 2 évaluant eryaspase pour le traitement du cancer du sein triple négatif
26/06/2019
LYON, France, 26 juin 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYTECH) (Euronext Paris : ERYP - Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des [...]
OraSure Technologies and Others Join Forces for HIV Testing Day
26/06/2019
Free HIV tests will be available across the country to spread awareness for National HIV Testing Day on June 27. BETHLEHEM, Pa., June 26, 2019 (GLOBE NEWSWIRE) -- National HIV Testing Day will be commemorated on June 27 [...]
Forward Pharma A/S Announces Intention to Transfer its U.S. Public Listing to the Nasdaq Capital Market Stock Exchange
26/06/2019
COPENHAGEN, Denmark, June 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced its intention to transfer its public listing of American Depositary Shares from the Nasdaq Global [...]
Harvard Bioscience Subsidiary Data Sciences International Launches Hardware for Expanding Research Capabilities
26/06/2019
Designed to Acquire and Synchronize Pre-clinical Signals from Disparate Sources ST. PAUL, Minn. and HOLLISTON, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard [...]
VIVUS and Nordmark Amend Contract Manufacturing Agreement to Supply Current and Future Demand for PANCREAZE®
26/06/2019
-Companies will also collaborate to develop additional PANCREAZE dose formulations and an advanced formulation with an extended shelf life- CAMPBELL, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS [...]
Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts
26/06/2019
51% of subjects in Cohort 2 achieved complete clearance of all treatable warts VP-102 was well-tolerated with no serious adverse events reported Common warts affect approximately 22 million people in the United States [...]
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
26/06/2019
ATI-502 did not achieve statistical superiority at the primary or secondary endpoints due to high rates of disease resolution in vehicle-treated patients WAYNE, Pa., June 26, 2019 (GLOBE NEWSWIRE) -- Aclaris [...]
Community pharmacies tap into new revenue, greatly improve community health with leading FDS solutions for population health, analytics and financial reconciliation
26/06/2019
Community pharmacies tapping into the latest solutions from FDS to uncover new paths to growth, significantly increase profit and strengthen community and patient health FORT WORTH, Texas, June 26, 2019 (GLOBE NEWSWIRE [...]
Changes to the financial calendar 2018/19
26/06/2019
Company announcement No 09/2019 Attachment No 09 2019_Changes to Financial Calendar 2018_2019
Interim Report September 1, 2018 - May 31, 2019
26/06/2019
Company Announcement No 08, 2019 Solid sales growth and profitability in Q3, but reduced organic growth outlook for the year. Attachment No 08 2019 Company announcement Q3 FY19
Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
26/06/2019
FDA approves Dupixent ® (dupilumab) for chronic rhinosinusitis with nasal polyposis First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP) Dupixent [...]
Sanofi : La FDA approuve Dupixent® (dupilumab) dans le traitement de la polypose nasosinusienne
26/06/2019
La FDA approuve Dupixent ® (dupilumab) dans le traitement de la polypose nasosinusienne Premier médicament biologique destiné à l’adulte souffrant de polypose nasosinusienne (PNS) inadéquatement contrôlée Dupixent [...]
AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease
26/06/2019
Paris, June 26, 2019, 7pm Interim results of masitinib study in Alzheimer’s disease: positive trend of efficacy in one of the doses tested Final analysis will be available in Q4 2019 AB Science SA (NYSE Euronext - [...]

Pages